A Nano-pharmaceutical Platform for Creating Artificial Vaccines

Award Information
Agency:
Department of Defense
Amount:
$150,000.00
Program:
SBIR
Contract:
W911NF-11-C-0267
Solitcitation Year:
2011
Solicitation Number:
2011.1
Branch:
Defense Health Program
Award Year:
2011
Phase:
Phase I
Agency Tracking Number:
O111-H01-3056
Solicitation Topic Code:
OSD11-H01
Small Business Information
Parabon NanoLabs, Inc.
11260 Roger Bacon Drive, Suite 406, Reston, VA, -
Hubzone Owned:
N
Woman Owned:
N
Socially and Economically Disadvantaged:
N
Duns:
828881305
Principal Investigator
 Steven Armentrout
 CEO
 (703) 689-9689
 steve@parabon.com
Business Contact
 Paula Gawthorp-Armentrout
Title: Corporate Secretary
Phone: (703) 689-9689
Email: paula@parabon.com
Research Institution
N/A
Abstract
In this project, Parabon NanoLabs (PNL) will demonstrate the feasibility of extending its Essemblix(tm) Drug Development Platform, a combination of computer-aided design (CAD) software and DNA nano-fabrication technology, to produce Essemblix-V, a platform for creating artificial vaccines from a predefined set of"building block molecules"assembled on DNA origami. Given an epitope for a potential biothreat agent, Essemblix-V will allow the production of artificial epitopes (hereafter"mimotopes") that can mimic the original epitope sufficiently to bind target antibodies with high affinity. Additionally, Essemblix-V will allow mimotopes to be arranged on origami in complex presentation patterns known to elicit rapid and potent immune response via T cell-independent activation. As a proof of concept, PNL will demonstrate the feasibility of (i) enhancing its existing inSequio(tm) CAD software to support the design of mimotopes with building block molecules; and (ii) modulating, through rational design, the charge distribution and hydrophobicity of specific mimotopes, since these attributes can affect conformation and stability. Prototype mimotopes will be created for /Borrelia burgdorferi/ and ricin toxin and their affinity to specific monoclonal antibodies will be demonstrated via ELISA assay. In Phase 2, artificial vaccines will be created for theses targets and evaluated in a murine model.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government